Growing evidence suggests that amino acid sequence approaches represent a exciting emerging frontier for malignant care. Unlike traditional medication, these approaches can be engineered to selectively attack tumor growth while minimizing impact to non-cancerous cells. This specificity offers the chance for better outcomes and less adverse reactio